摘要 : Background: Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia (CML). Skin rashes are common, occurring in about a quarter of patients treated, and are generally mild. The commonest ra... 展开
作者 | Bergman~ Joel C. Ly~ Thai Yen Keating~ Margaret-Mary Hull~ Peter R. |
---|---|
作者单位 | |
期刊名称 | 《Journal of cutaneous medicine and surgery》 |
总页数 | 3 |
语种/中图分类号 | 英语 / R75 |
关键词 | dasatinib neutrophilic dermatosis fixed drug eruption Sweet disease recurrent |
馆藏号 | N2007EPST0002240 |